Mini review highlights outbreaks and high case-fatality rate of Nipah virus in South Asia, suggesting urgent need for therapeutics and surveillance.
Nipah virus (Niv), a zoonotic paramyxovirus of the Henipaviral genus, continues to pose recurrent epidemic threats across South and Southeast Asia. Initially recognized in Malaysia (1998–99) and later established as endemic in Bangladesh and India, its high case-fatality rate (40–90%) and absence of licensed therapeutics make it a pathogen of pandemic concern. Recent outbreaks in Kerala during 2018, 2021, and 2023 reaffirm the need for an integrated One Health approach, cross-border surveillance, and accelerated therapeutic research.
No takes yet. Share an insight, caveat, or question.
Kamalakar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: